Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy.

Int J Mol Sci · 2024 · PMC10931688 · PMID 38474108

Europe PMC DOI

hedged sentence

0.1800

closest p · 3.6× alpha

0.1800

boldest claim

The sentences

showed a trendp = 0.18not close (p > 0.1)

Patients with higher than median serum sCD163 levels showed a trend for more unfavorable overall survival ( p = 0.18, HR 1.4, 95% CI 16.7–43.2 for patients with values below median and 61.1–160.8 for patients with values above median).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.